Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
DEER PARK, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that company management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference from February 24th through February 26th. About Eton PharmaceuticalsEton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing a...
With the business potentially at an important milestone, we thought we'd take a closer look at Eton Pharmaceuticals...
Eton Pharmaceuticals Inc (NASDAQ: ETON) has sold its neurology portfolio that includes lamotrigine (ET-105), zonisamide (ET-104), and topiramate (ET-101) product candidates, to Azurity Pharmaceuticals. The marketing applications for all three candidates are currently under review with the FDA. Azurity will be responsible for commercialization following regulatory approval, though Eton will support Azurity in the transition and through regulatory approval. "This transaction allows us to focus on ...
Eton to receive up to $45 million plus royalties on product sales DEER PARK, Ill., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has sold its neurology portfolio to Azurity Pharmaceuticals. The portfolio includes Eton’s lamotrigine (ET-105), zonisamide (ET-104), and topiramate (ET-101) product candidates, which have...
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
DEER PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc (LSE AIM: DNL). Eton Pharmaceuticals currently commercializes ALKINDI® SPRINKLE in the United States as a replacement therapy for Adrenocortical Insufficiency (AI) in children under...
Application Assigned a PDUFA Date of August 6, 2021DEER PARK, Ill., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s new drug application (NDA) for topiramate oral solution. The application has been assigned a Prescription Drug User Fee Act (PDUF...